Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 26, 2023
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
[ Wed, Apr 26th 2023
] - WOPRAI
Sumant Kulkarni Initiated (STOK) at Strong Buy and Held Target at $24 on, Apr 26th, 2023
Sumant Kulkarni of Canaccord Genuity, Initiated "Stoke Therapeutics, Inc." (STOK) at Strong Buy and Held Target at $24 on, Apr 26th, 2023.
Sumant has made no other calls on STOK in the last 4 months.
There are 5 other peers that have a rating on STOK. Out of the 5 peers that are also analyzing STOK, 0 agree with Sumant's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Sumant
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $25 on, Thursday, March 16th, 2023
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $28 on, Tuesday, March 7th, 2023
- Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $25 on, Tuesday, March 7th, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Tuesday, March 7th, 2023
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $20 on, Tuesday, March 7th, 2023
